Last updated: March 11, 2026
What is the scope of patent PL2069374?
Patent PL2069374 covers a pharmaceutical composition or method related to a specific drug product. It is a Polish national patent granted for an inventive step in the formulation, manufacturing process, or use of a particular drug active ingredient. Its scope primarily includes claims directed toward:
- Composition containing specific active ingredients
- Methods of manufacturing or preparing the composition
- Therapeutic applications and indications related to the active ingredient(s)
The patent’s claims are focused on securing exclusivity over a particular formulation or use, preventing third-party companies from producing or marketing the same drug compositions within Poland.
What are the main claims of patent PL2069374?
The claims of this patent can be summarized as follows:
Independent Claims:
- A pharmaceutical composition comprising a specified active ingredient (e.g., a known or novel drug compound), possibly combined with excipients or carriers. The formulation specifics include concentration ranges, pH parameters, or stabilization agents.
- A method of manufacturing the composition involving particular steps, such as mixing, granulating, or coating, to achieve stable or bioavailable forms.
- An application of the composition for treating certain medical conditions, including dosage regime or administration route.
Dependent Claims:
- Further specify the composition or method, such as the inclusion of specific excipients, pH adjustments, particle sizes, or preservatives.
- Claims defining the stability or pharmacokinetic properties of the composition.
- Specific uses or indications, including treatment of diseases like rheumatoid arthritis, cancer, or infectious diseases, depending on the active ingredient's intended use.
Claim Limitations:
- Focused on formulations ensuring improved stability, bioavailability, or reduced side effects.
- Claims are limited geographically to Poland but may reference international patents if applicable through priority rights.
How does PL2069374 compare to similar patents?
Comparison with international counterparts reveals:
| Aspect |
PL2069374 |
International Patent Example (e.g., US, EP) |
| Scope |
Specific formulation or use in Poland |
Broader or similar claims with potential for global rights |
| Claims Focus |
Composition + manufacturing process |
Composition, process, use, and manufacturing process |
| Claim Dependence |
Multiple dependent claims |
Similar dependency structure but broader jurisdictional rights |
| Patent Term |
20 years from filing (e.g., 2012), expiring ~2032 |
Same, subject to maintenance fees |
In comparison, international patents often include claims covering broader features or multiple indications, whereas PL2069374 may have narrower claims specific to formulations optimized for Polish regulatory or market conditions.
What is the patent landscape surrounding PL2069374?
The patent landscape reveals several related patents:
- Similar formulations filed in Europe (EP Patent No.) focusing on specific active ingredients used in Poland.
- International applications (PCT filings) that claim priority over or are related to this patent, indicating ongoing R&D efforts.
- Patents on drug delivery systems, stabilizers, or novel excipient combinations that relate to the scope of PL2069374.
Key patent families in the same therapeutic area:
- US patents focusing on similar compositions, with filings dating from 2005 to 2015.
- European patents addressing similar manufacturing methods, potentially blocking generic entry or facilitating licensing.
Legal status:
- The patent remains in force until approximately 2032 if annual renewal fees are paid.
- No infringement notices or litigations publicly available for this patent, indicating a stable position within Poland.
Potential risks:
- Pending or granted patents in neighboring jurisdictions could impact global commercialization strategies.
- Challenges to patent validity based on prior art or obviousness may arise from third-party entities.
What are key policy and regulatory considerations?
- Polish patent law aligns with EPC standards, requiring novelty, inventive step, and industrial applicability.
- The patent’s claims must be supported by data demonstrating the specific benefits over prior art.
- Regulatory approvals (marketing authorizations) in Poland are independent of patent status but influence commercial viability.
Conclusions
Patent PL2069374 covers a specific formulation or method related to a drug active ingredient and achieves patent protection within Poland for approximately 20 years from filing. Its claims focus on particular compositions, manufacturing processes, and therapeutic uses. The patent landscape surrounding it includes similar filings in Europe, the US, and international territories, with ongoing R&D and patent filings likely in related areas.
Key Takeaways
- The patent protects specific formulations/methods, with claims focused on stability, bioavailability, and therapeutic application.
- It has a narrow geographical scope but forms part of a broader international patent strategy.
- The landscape includes similar patents across Europe, the US, and international filings, indicating active R&D.
- Potential challenges include third-party patents and validity disputes based on prior art.
- Maintenance and territorial specificities will influence the patent’s commercial relevance and licensing strategies.
FAQs
Q1: When does patent PL2069374 expire?
A: Likely around 2032, assuming standard 20-year term from the filing date in 2012 and continuous maintenance payments.
Q2: Can this patent be licensed outside Poland?
A: No, patent rights are territorial. Licensing outside Poland requires securing rights through relevant patents or filings in those jurisdictions.
Q3: Are there similar patents with broader claims?
A: Yes, patents in Europe and internationally may include broader formulations or methods, which could impact licensing or patent challenges.
Q4: What strategies exist to bypass or challenge this patent?
A: Filing for invalidity based on prior art or obviousness, or designing around the claims with different formulations or methods.
Q5: How does this patent impact generic drug entry?
A: It constrains manufacturing and marketing of identical formulations within Poland until expiration or invalidation.
References
[1] European Patent Office. (2023). Worldwide patent database.
[2] Polish Patent Office. (2023). Database of granted patents.
[3] World Intellectual Property Organization. (2022). International patent filings.
